Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (August 2026)
13 slides from Bayer's technical presentation, Aug 21, 2026
Slide 1: Effects of finerenone in patients with hypertensive nephropathy
Effects of finerenone in patients with hypertensive nephropathy Hiddo J.L. Heerspink On behalf of Jelle M. Beernink, Rajiv Agarwal, David Z.I. Cherney, Carolyn S.P. Lam, Brendon L. Neuen, Vlado Perkovic, Katherine R. Tuttle, Pantelis Sarafidis, Niels Jongs, J. David Smeijer, Meike Brinker, Juliana D
Slide 2: Introduction
Introduction Hypertensive nephropathy is a common cause of CKD and is associated with substantial residual risk of kidney function decline despite treatment with contemporary guideline-directed therapies*,1–3 MR Overactivation of the mineralocorticoid receptor is implicated in the pathophysiology of
Slide 3: FIND-CKD trial slows CKD progression in participants without diabetes
Introduction The FIND-CKD trial demonstrated that finerenone slows CKD progression in participants with CKD without diabetes1 Total eGFR slope* Kidney–cardiovascular composite§ 2 30 0 HR=0.77 (95% CI 0.60, 0.99) from baseline (ml/min/1.73 m2) Cumulative incidence (%) –2 Mean (95% CI) eGFR change 25
Slide 4: FIND-CKD study design
FIND-CKD study design1,2 Finerenone 10 or 20 mg od* (n=793) N=1584 R 1:1 Placebo (n=791) Visits at screening, baseline and months 1, 3, 6, 9 and 12; thereafter every 4 months till end of study End of treatment Follow-up Month 32 1 month post-treatment Key inclusion criteria Key exclusion criteria •
Slide 5: FIND-CKD hypertensive nephropathy subgroup analysis
FIND-CKD hypertensive nephropathy subgroup analysis FIND-CKD included a broad population with common Outcomes assessed in the overall FIND-CKD population were evaluated for non-diabetic CKD aetiologies well represented1 participants with investigator-reported hypertensive nephropathy at baseline Oth
Slide 6: Baseline characteristics
Baseline characteristics Characteristic Finerenone Placebo Overall HTN Characteristic Finerenone Placebo Overall HTN (n=234) (n=225) (N=459) (n=234) (n=225) (N=459) Age, years, mean (SD) 61.2 (12.8) 61.3 (13.6) 61.2 (13.2) Medical history, n (%) Atherosclerotic CVD 49 (20.9) 57 (25.3) 106 (23.1) Sex
Slide 7: eGFR slope
eGFR slope Change in eGFR from baseline over time* eGFR slopes stratified by baseline SBP Finerenone Placebo Finerenone Placebo Total slope§ Chronic slope¶ 2 0 Change from baseline in eGFR SBP <130 SBP ≥130 SBP <130 SBP ≥130 –2 mmHg mmHg mmHg mmHg 1.1 0 (ml/min/1.73 m2) eGFR slope (ml/min/1.73 m2) –
Slide 8: Secondary efficacy outcomes: kidney–CV composite and kidney outcome
Secondary efficacy outcomes Composite kidney–CV outcome* Kidney failure# or sustained ≥57% eGFR decrease 30 HR=0.61 (95% CI 0.38, 0.99) 30 HR=0.61 (95% CI 0.36, 1.03) Cumulative incidence (%) Cumulative incidence (%) 25 25 Placebo Placebo 20 No. of participants with event: 42 (18.7%) 20 No. of parti
Slide 9: Secondary efficacy outcomes: HHF or CV death, kidney failure or ≥40% eGFR decrease
Secondary efficacy outcomes HHF or CV death Kidney failure* or sustained ≥40% eGFR decrease 10 HR=0.87 (95% CI 0.29, 2.59) 40 HR=0.73 (95% CI 0.50, 1.07) Cumulative incidence (%) Cumulative incidence (%) 8 Placebo Placebo 30 No. of participants with event: 7 (3.1%) No. of participants with event: 62
Slide 10: Exploratory outcome: change from baseline in UACR
Exploratory outcome Change from baseline in UACR over time 30 Placebo 20 Median UACR, mg/g (Q1, Q3) at baseline Finerenone Change from baseline in UACR (%) Finerenone: 777.6 (552.8, 1230.7) 10 Placebo: 843.6 (575.3, 1266.2) –2.9% 0 –10 –20 +18.2% –30 –40 –50 Treatment –33% –36% –39% –60 difference,
Slide 11: Exploratory outcomes: systolic blood pressure and serum potassium
Exploratory outcomes Change from baseline in systolic blood pressure Change from baseline in serum potassium 4.00 0.40 Change from baseline (mmHg) 2.00 0.30 Change from baseline (mmol/l) 0.00 0.20 -2.00 0.10 -4.00 0.00 -6.00 -0.10 -8.00 Mean blood pressure at baseline: Mean (SD) serum potassium at b
Slide 12: Investigator-reported adverse events
Investigator-reported adverse events Finerenone (n=234) Placebo (n=225) 100 Adverse events Serious adverse events Hyperkalaemia* 80 67.5 Participants (%) 60.4 60 40 20.5 21.3 20 17.1 9.8 1.7 1.8 1.3 0.9 2.7 1.3 0.9 0.0 0.0 0.4 0.0 0.0 0 Any Leading to Any Leading to Fatal Any Leading to Requiring Fa
Slide 13: Summary
Summary In FIND-CKD participants with Safety events were This prespecified subgroup hypertensive nephropathy, consistent with the overall analysis supports blockade of finerenone versus placebo: trial population mineralocorticoid receptor overactivation as a • Slowed CKD progression Hyperkalaemia oc